Akero Therapeutics Acquisition Finalized, Shares Delisted from Nasdaq

The publicly traded chapter for Akero Therapeutics has officially closed. The company’s shares, previously listed under the ticker symbol “AKRO” on the Nasdaq, have been removed from trading boards following the completion of its acquisition by Danish pharmaceutical leader Novo Nordisk. The deal, which received shareholder approval, was formally concluded on December 9.

Trading in Akero Therapeutics stock was halted prior to market open on December 10. The biopharma firm now operates as a wholly-owned subsidiary within the Novo Nordisk corporate structure.

Shareholder Payout Structure: Immediate and Contingent

For investors who held their shares through the acquisition, the transaction triggers an immediate cash payout. Novo Nordisk is paying $54.00 per share, a figure that values the equity portion of the agreement at approximately $4.7 billion.

Should investors sell immediately? Or is it worth buying Akero Therapeutics?

Beyond this upfront payment, the deal includes a potential future component. Shareholders will receive one non-tradable Contingent Value Right (CVR) for each share they held. This CVR entitles them to an additional cash payment of $6.00 per share, contingent upon the achievement of specific U.S. regulatory milestones for the drug candidate efruxifermin (EFX). This structure means the total eventual value for shareholders could reach up to $60.00 per share.

Strategic Focus on Promising Drug Candidate

The acquisition centers on Akero’s lead product, efruxifermin, which is being developed as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The contingent payout is specifically tied to regulatory approval milestones for EFX in treating MASH-related compensated cirrhosis.

With the delisting effective, Akero Therapeutics no longer exists as an independent public company. For former shareholders, attention now shifts to receiving the immediate cash payment and monitoring the progress of the CVR milestones within Novo Nordisk’s development pipeline. Further trading of Akero Therapeutics stock is no longer possible.